Notizie su ALK-Abelló

Ultime notizie

Titoli nella lingua originale della fonte.

• 
  ALK-Abelló Pharmaceuticals Inc Announces Positive Funding Recommendation from Canada's Drug Agency for neffy® for the Emergency Treatment of Allergic Reactions (Anaphylaxis) (si apre in una nuova scheda)

  1 ott 2026

• ALK expands strategic tablet supply partnership with Catalent (si apre in una nuova scheda)

  30 set 2026

• Why ALK-Abelló (CPSE:ALK B) Is Getting Attention Today (si apre in una nuova scheda)

  23 set 2026

• 
  ALK appoints Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy (si apre in una nuova scheda)

  21 set 2026

• ALK to present at the Morgan Stanley Global Healthcare Conference in New York (si apre in una nuova scheda)

  11 set 2026

• Alk-Abello AS (AKBLF) (Q2 2026) Earnings Call Highlights: Strong Tablet Sales and Raised ... (si apre in una nuova scheda)

  20 ago 2026

• ALK appoints Jacob Glenting as head of Global R&D (si apre in una nuova scheda)

  20 ago 2026

• Six-month interim report (Q2) 2026 (unaudited) (si apre in una nuova scheda)

  20 ago 2026

• ALK’s tree pollen and house dust mite tablets now recommended by NICE for paediatric treatment in the UK health system (si apre in una nuova scheda)

  14 ago 2026

• Invitation to the presentation of ALK’s first six months (Q2) 2026 results on Thursday, 20 August 2026 (si apre in una nuova scheda)

  13 ago 2026

• Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada (si apre in una nuova scheda)

  5 ago 2026

• Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight (si apre in una nuova scheda)

  27 lug 2026

• Is It Too Late To Consider ALK-Abelló (CPSE:ALK B) After Strong Multi‑Year Gains? (si apre in una nuova scheda)

  5 giu 2026

• ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026 (si apre in una nuova scheda)

  4 giu 2026

• ALK to present at the Jefferies Global Healthcare Conference in New York (si apre in una nuova scheda)

  29 mag 2026

• Three-month interim report (Q1) 2026 (unaudited) (si apre in una nuova scheda)

  4 mag 2026

• ALK upgrades its full-year outlook (si apre in una nuova scheda)

  4 mag 2026

• Assessing ALK Abelló (CPSE:ALK B) Valuation After Strong Recent Share Price Momentum (si apre in una nuova scheda)

  2 mag 2026

• Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026 (si apre in una nuova scheda)

  28 apr 2026

• Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff (si apre in una nuova scheda)

  8 apr 2026